Amyris, Inc. (NASDAQ:AMRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage currently has a $3.75 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 12.95% from the stock’s current price.

According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “

AMRS has been the topic of a number of other reports. ValuEngine raised Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Cowen and Company set a $4.00 price objective on Amyris and gave the company a “hold” rating in a report on Thursday, August 17th. Finally, HC Wainwright set a $15.00 price objective on Amyris and gave the company a “buy” rating in a report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Amyris presently has an average rating of “Hold” and an average price target of $20.69.

Shares of Amyris (NASDAQ AMRS) traded down 1.19% during mid-day trading on Wednesday, hitting $3.32. The company had a trading volume of 215,747 shares. Amyris has a 12-month low of $0.21 and a 12-month high of $18.15. The firm’s market cap is $124.85 million. The firm’s 50 day moving average is $2.90 and its 200-day moving average is $4.51.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.35). The company had revenue of $25.68 million during the quarter, compared to analysts’ expectations of $23.68 million. During the same quarter last year, the company earned ($0.06) EPS. The firm’s revenue for the quarter was up 167.5% on a year-over-year basis. On average, equities analysts expect that Amyris will post ($3.42) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Amyris, Inc. (AMRS) Lifted to “Buy” at Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/04/amyris-inc-amrs-lifted-to-buy-at-zacks-investment-research.html.

An institutional investor recently raised its position in Amyris stock. Bank of New York Mellon Corp boosted its position in shares of Amyris, Inc. (NASDAQ:AMRS) by 16.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,768 shares of the biotechnology company’s stock after buying an additional 4,603 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.17% of Amyris worth $104,000 as of its most recent SEC filing. Institutional investors own 19.79% of the company’s stock.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.